fda gpha cmc workshop post implementation update of the ... · –api lot/batch 3 or 1 or 2 or a...
TRANSCRIPT
![Page 1: FDA GPHA CMC Workshop Post Implementation Update of the ... · –API Lot/batch 3 or 1 or 2 or a mix of 1 & 2 ANDA batch 3 –Inhalation dosage forms to use three discrete lots for](https://reader035.vdocuments.site/reader035/viewer/2022070716/5ed9e54f6d86580bfd101f04/html5/thumbnails/1.jpg)
1
FDA – GPHA CMC Workshop
Post Implementation Update of the ANDA Stability Guidance(s)
Radhika Rajagopalan, Ph.D.
FDA/CDER/OPQ/OLDP
May17-18, 2016
![Page 2: FDA GPHA CMC Workshop Post Implementation Update of the ... · –API Lot/batch 3 or 1 or 2 or a mix of 1 & 2 ANDA batch 3 –Inhalation dosage forms to use three discrete lots for](https://reader035.vdocuments.site/reader035/viewer/2022070716/5ed9e54f6d86580bfd101f04/html5/thumbnails/2.jpg)
Presentation today contains…….
• Opinions expressed are those of the presenter…
•2
![Page 3: FDA GPHA CMC Workshop Post Implementation Update of the ... · –API Lot/batch 3 or 1 or 2 or a mix of 1 & 2 ANDA batch 3 –Inhalation dosage forms to use three discrete lots for](https://reader035.vdocuments.site/reader035/viewer/2022070716/5ed9e54f6d86580bfd101f04/html5/thumbnails/3.jpg)
Where Are We Today?
•3
Goal: Align stability expectations for ANDAs with ICH
August 27, 2013: Published draft Q&A guidance with implementation date
June 20, 2014: Implemented the Stability Guidance
OLDP Continues to review & approve GDUFA ANDAS using the Guidances and supports activities
![Page 4: FDA GPHA CMC Workshop Post Implementation Update of the ... · –API Lot/batch 3 or 1 or 2 or a mix of 1 & 2 ANDA batch 3 –Inhalation dosage forms to use three discrete lots for](https://reader035.vdocuments.site/reader035/viewer/2022070716/5ed9e54f6d86580bfd101f04/html5/thumbnails/4.jpg)
ANDA CMC Review in OLDP
•4
• Infancy through maturity: Development planning, process planning, building in quality, BE/PK studies, site qualification should all be done ahead of time along with generation of three batches, 6 months’ stability data by ANDA applicant
• ANDA review in OLDP: Involvement will be at the final stages of DP selected for commercialization (market approval)
• Pathway to achieve GDUFA review time line goal and complete product quality assessment to make a recommendation
![Page 5: FDA GPHA CMC Workshop Post Implementation Update of the ... · –API Lot/batch 3 or 1 or 2 or a mix of 1 & 2 ANDA batch 3 –Inhalation dosage forms to use three discrete lots for](https://reader035.vdocuments.site/reader035/viewer/2022070716/5ed9e54f6d86580bfd101f04/html5/thumbnails/5.jpg)
ANDA CMC Review
• GDUFA timelines for review are immensely helped by the three batch and longer duration stability data
• API lot variation is helpful in assessing product consistency
• Information Request process is mainly used by Product, Process, Biopharmaceutics, and other disciplines to communicate and conclude the review towards a recommendation
• Increased amount of quality data are very much helpful in decision making
•5
![Page 6: FDA GPHA CMC Workshop Post Implementation Update of the ... · –API Lot/batch 3 or 1 or 2 or a mix of 1 & 2 ANDA batch 3 –Inhalation dosage forms to use three discrete lots for](https://reader035.vdocuments.site/reader035/viewer/2022070716/5ed9e54f6d86580bfd101f04/html5/thumbnails/6.jpg)
What are repeating Questions?
•6
![Page 7: FDA GPHA CMC Workshop Post Implementation Update of the ... · –API Lot/batch 3 or 1 or 2 or a mix of 1 & 2 ANDA batch 3 –Inhalation dosage forms to use three discrete lots for](https://reader035.vdocuments.site/reader035/viewer/2022070716/5ed9e54f6d86580bfd101f04/html5/thumbnails/7.jpg)
Where are we today? What are repeating Q?
• Using at least two discrete batches/lots of DS to manufacture three batches of DP
– API Lot/batch 1 ANDA batch 1
– API Lot/batch 2 ANDA batch 2
– API Lot/batch 3 or 1 or 2 or a mix of 1 & 2 ANDA batch 3
– Inhalation dosage forms to use three discrete lots for 3 batches of ANDA DP (addressed in footnotes)
– Certainly ties in with quality demonstration of product, process, and stability issues
– DMFs are complying with ICH stability requirements
•7
![Page 8: FDA GPHA CMC Workshop Post Implementation Update of the ... · –API Lot/batch 3 or 1 or 2 or a mix of 1 & 2 ANDA batch 3 –Inhalation dosage forms to use three discrete lots for](https://reader035.vdocuments.site/reader035/viewer/2022070716/5ed9e54f6d86580bfd101f04/html5/thumbnails/8.jpg)
Why 6 months of stability at submission?
• Harmonized expectations, and time periods across climatic zones
• Anda filing requirement: 3, and 6 months of accelerated and long-term data (6 months intermediate data if needed); 1 or 2 months data not needed (test at your discretion); GPHA request to file ANDA with 6 months data is honored
• Stability Q&A guidance, Section E, Q1: 0 (initial), 3 and 6 months
•8
![Page 9: FDA GPHA CMC Workshop Post Implementation Update of the ... · –API Lot/batch 3 or 1 or 2 or a mix of 1 & 2 ANDA batch 3 –Inhalation dosage forms to use three discrete lots for](https://reader035.vdocuments.site/reader035/viewer/2022070716/5ed9e54f6d86580bfd101f04/html5/thumbnails/9.jpg)
Question on the same topic….
• Should studies be continued to 6 months if the product fails at 3 months (40/75)?
– For semisolids ICH Q1A (R2) allows for appearance change; nonetheless our recommendation is not to stop, but continue to 6 months and report data [evaluate your product]
– If your plans are to file a submission of that product-formula-pkg, then continue and do not stop the studies; report significant changes seen along with your assessment
– Option to consider: Wherein significant changes at 6 months’ accelerated, and intermediate conditions are seen, submit 12 months long-term data at the time of submission to avoid receiving a Major CR letter (i.e., generation of data per ICH requirement to aid in review timeline and regulatory decision)
•9
![Page 10: FDA GPHA CMC Workshop Post Implementation Update of the ... · –API Lot/batch 3 or 1 or 2 or a mix of 1 & 2 ANDA batch 3 –Inhalation dosage forms to use three discrete lots for](https://reader035.vdocuments.site/reader035/viewer/2022070716/5ed9e54f6d86580bfd101f04/html5/thumbnails/10.jpg)
Continued….
• If stability data are submitted that shows product failure (or significant change) at 6 months accelerated, and 6 months intermediate condition, the ANDA will receive a complete response letter
• Notice in the above case the applicant may consider submitting 12 months long-term data at the time of submission
•10
![Page 11: FDA GPHA CMC Workshop Post Implementation Update of the ... · –API Lot/batch 3 or 1 or 2 or a mix of 1 & 2 ANDA batch 3 –Inhalation dosage forms to use three discrete lots for](https://reader035.vdocuments.site/reader035/viewer/2022070716/5ed9e54f6d86580bfd101f04/html5/thumbnails/11.jpg)
When is day one in stability studies?
• Product manufactured, tested (days 1 through 15), and release COA issued; product placed in stability ovens on day 21 in the following conditions
– Accelerated, Long-term, and Intermediate
• Day 21 now becomes day 1 for all three conditions
•11
COA Day 90 Day 1 in
ovens
Day 180
![Page 12: FDA GPHA CMC Workshop Post Implementation Update of the ... · –API Lot/batch 3 or 1 or 2 or a mix of 1 & 2 ANDA batch 3 –Inhalation dosage forms to use three discrete lots for](https://reader035.vdocuments.site/reader035/viewer/2022070716/5ed9e54f6d86580bfd101f04/html5/thumbnails/12.jpg)
Justification for Smaller Batch Size below ICH recommended threshold
• 1. Orphan drug indications (RLD all indications on the label granted orphan status)
• 2. Controlled DS requiring DEA allotment
• 3. Commitment to submit PAS if scale is larger than exhibit scale
•12
![Page 13: FDA GPHA CMC Workshop Post Implementation Update of the ... · –API Lot/batch 3 or 1 or 2 or a mix of 1 & 2 ANDA batch 3 –Inhalation dosage forms to use three discrete lots for](https://reader035.vdocuments.site/reader035/viewer/2022070716/5ed9e54f6d86580bfd101f04/html5/thumbnails/13.jpg)
Justification for Smaller Batch Size
• Note the requirement for 2 API lots (or 3) still applies, and only the size of the ANDA DP batch is reduced
• Scale up for 1 & 2 is not impacted (follow SUPAC- beyond 10 times)
• Item 3 requires a prior approval supplement to increase the scale, and for all other changes covered by Supac guidances please refer to them
•13
![Page 14: FDA GPHA CMC Workshop Post Implementation Update of the ... · –API Lot/batch 3 or 1 or 2 or a mix of 1 & 2 ANDA batch 3 –Inhalation dosage forms to use three discrete lots for](https://reader035.vdocuments.site/reader035/viewer/2022070716/5ed9e54f6d86580bfd101f04/html5/thumbnails/14.jpg)
Sample ‘retention’ of Drug product
•14
![Page 15: FDA GPHA CMC Workshop Post Implementation Update of the ... · –API Lot/batch 3 or 1 or 2 or a mix of 1 & 2 ANDA batch 3 –Inhalation dosage forms to use three discrete lots for](https://reader035.vdocuments.site/reader035/viewer/2022070716/5ed9e54f6d86580bfd101f04/html5/thumbnails/15.jpg)
Retention Sample size – Drug Product
• Samples from 3 (three) submission batches need to be retained
• Note: not the entire batch
• Enough samples to perform 4 times x 3 (batches) each test listed in your specification
• Reserve Samples 21 CFR 211.170 (a) and (b) – applies to both commercial and submission batches per GMPs
• 314.50 makes sample retention a filing requirement for DP as it is under evaluation
– FDA lab testing, visual evaluation, consults across FDA offices
•15
![Page 16: FDA GPHA CMC Workshop Post Implementation Update of the ... · –API Lot/batch 3 or 1 or 2 or a mix of 1 & 2 ANDA batch 3 –Inhalation dosage forms to use three discrete lots for](https://reader035.vdocuments.site/reader035/viewer/2022070716/5ed9e54f6d86580bfd101f04/html5/thumbnails/16.jpg)
Acknowledgements
• FDA OPQ, OLDP and GPhA
• THANK YOU
•16